Ekso Bionics Notches Medicare Win for Indego Personal Exoskeleton

Ekso Bionics announced that the Centers for Medicare & Medicaid Services (CMS) has proposed a payment level for its exoskeleton technology.
 
The Pricing, Data Analysis, and Coding (PDAC) contractor for CMS completed its review of the Ekso Indego Personal and approved use of Healthcare Common Procedure Coding System (HCPCS) Code K1007 to bill Medicare for the device. CMS proposed a payment level of $94,617 for devices within this code and expects to announce in February 2024 the final payment determination before it takes effect on April 1, 2024.
 
Ekso Indego Personal is modular, lightweight, and portable, meant for use in most home and community environments. The device has an advanced gait mode enabling the user to reach faster walking speeds.
 
“We are very pleased that CMS recognizes the potential health benefits that exoskeletons like our Ekso Indego Personal can have on the daily lives of individuals with spinal cord injuries (SCIs),” said Scott Davis, CEO of Ekso Bionics. “Once the reimbursement code takes effect, we expect that our Ekso Indego Personal will be accessible to those eligible within the SCI community at a substantially lower cost. We believe this important milestone serves as an inflection point for this unique device that will improve health outcomes and enhance quality of life for individuals living with an SCI.”